Pre-made Simtuzumab biosimilar ( Whole mAb, anti-LOXL2 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-522
Anti-LOXL2 therapeutic antibody (Pre-made Simtuzumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Simtuzumab (INN; formerly GS 6624) is a humanized monoclonal antibody designed for the treatment of fibrosis. It binds to LOXL2 and acts as an immunomodulator. In January 2016, Gilead Sciences terminated its Phase 2 clinical study in patients with idiopathic pulmonary fibrosis (IPF) due to lack of efficacy.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-LOXL2 therapeutic antibody (Pre-made Simtuzumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Arresto Biosciences;Gilead Sciences|
|Conditions Discontinued||Colorectal cancer;Hepatic fibrosis;Idiopathic pulmonary fibrosis;Liver cirrhosis;Myelofibrosis;Non-alcoholic steatohepatitis;Pancreatic cancer;Primary sclerosing cholangitis|